Stryker PE Ratio 2006-2018 | SYK
Current and historical price to earnings ratio for Stryker (SYK) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for Stryker as of August 17, 2018 is 24.56.
| Stryker Annual PE Ratio |
|---|
| Stryker Quarterly PE Ratio |
|---|
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $63.571B | $12.444B |
| Stryker Corporation is one of the world's leading medical technology companies and together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $122.465B | 18.95 |
| Abbott Laboratories (ABT) | United States | $113.540B | 23.79 |
| Boston Scientific (BSX) | United States | $47.586B | 24.75 |
| Baxter (BAX) | United States | $38.489B | 26.20 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.204B | 16.19 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $15.640B | 0.00 |
| ResMed (RMD) | United States | $15.244B | 30.25 |
| Perrigo (PRGO) | Ireland | $9.983B | 14.17 |
| Bio-Rad Laboratories (BIO) | United States | $9.444B | 60.64 |
| Canopy Growth (CGC) | Canada | $7.445B | 0.00 |
| Hill-Rom Holdings (HRC) | United States | $6.341B | 21.51 |
| ICU Medical (ICUI) | United States | $6.026B | 40.83 |
| Haemonetics (HAE) | United States | $5.351B | 48.83 |
| Insulet (PODD) | United States | $5.209B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $4.408B | 0.00 |
| Neogen (NEOG) | United States | $4.360B | 69.38 |
| Hutchison China MediTech (HCM) | China | $3.903B | 0.00 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.778B | 0.00 |
| NuVasive (NUVA) | United States | $3.598B | 34.13 |
| National Vision Holdings (EYE) | United States | $3.054B | 67.43 |
| Quidel (QDEL) | United States | $2.769B | 56.74 |
| Phibro Animal Health (PAHC) | United States | $1.990B | 29.55 |
| NxStage Medical (NXTM) | United States | $1.846B | 0.00 |
| Cardiovascular Systems (CSII) | United States | $1.249B | 751.20 |
| Eagle Pharmaceuticals (EGRX) | United States | $1.176B | 34.73 |
| VAREX IMAGING (VREX) | United States | $1.130B | 18.47 |
| AtriCure (ATRC) | United States | $1.099B | 0.00 |
| Omeros (OMER) | United States | $1.016B | 0.00 |
| OraSure Technologies (OSUR) | United States | $1.001B | 65.44 |
| Owens & Minor (OMI) | United States | $0.990B | 10.59 |
| Surmodics (SRDX) | United States | $0.981B | 118.47 |
| TG Therapeutics (TGTX) | United States | $0.957B | 0.00 |
| Cerus (CERS) | United States | $0.922B | 0.00 |
| PetIQ (PETQ) | United States | $0.847B | 29.00 |
| MacroGenics (MGNX) | United States | $0.845B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.716B | 34.34 |
| Meridian Bioscience (VIVO) | United States | $0.632B | 21.59 |
| Insys Therapeutics (INSY) | United States | $0.574B | 0.00 |
| Evolus (EOLS) | United States | $0.527B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.515B | 16.01 |
| NanoString Technologies (NSTG) | United States | $0.417B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.363B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.325B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.324B | 20.86 |
| Quanterix (QTRX) | United States | $0.324B | 0.00 |
| Surface Oncology (SURF) | United States | $0.279B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.216B | 0.00 |
| Chimerix (CMRX) | United States | $0.195B | 0.00 |
| Fonar (FONR) | United States | $0.170B | 10.34 |
| Chembio Diagnostics (CEMI) | United States | $0.158B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.119B | 0.00 |
| Female Health (VERU) | United States | $0.115B | 0.00 |
| United-Guardian (UG) | United States | $0.086B | 18.83 |
| Trinity Biotech (TRIB) | Ireland | $0.085B | 25.25 |
| Oramed Pharmaceuticals (ORMP) | Israel | $0.082B | 0.00 |
| Neurotrope (NTRP) | United States | $0.075B | 0.00 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.064B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.061B | 0.00 |
| ImmuCell (ICCC) | United States | $0.037B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.036B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.032B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.025B | 0.00 |
| Senestech (SNES) | United States | $0.021B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
